MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,445 shares of the medical research company's stock after selling 32,945 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Edwards Lifesciences were worth $7,362,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of EW. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares during the period. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares during the period. Geode Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after purchasing an additional 126,194 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after purchasing an additional 696,965 shares during the period. Finally, Norges Bank purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $610,895,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the transaction, the vice president now directly owns 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. This trade represents a 16.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,692 shares of company stock valued at $4,822,074 in the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.19 during trading on Friday, reaching $74.98. The company's stock had a trading volume of 3,738,140 shares, compared to its average volume of 5,138,901. The company has a 50-day moving average price of $72.78 and a two-hundred day moving average price of $72.04. The firm has a market cap of $43.98 billion, a PE ratio of 10.76, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 EPS. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and a consensus price target of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.